查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1882974

敗血症抗生素市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032 年）

Septicemia Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 請詢問到貨日

價格

敗血症抗生素市場成長因素

由於全球細菌感染和血液相關併發症的增加，全球膿毒症抗生素市場持續擴張。根據本報告，預計該市場在 2024 年將達到 26.1 億美元，在 2025 年將達到 26.7 億美元。預計到 2032 年，該市場將成長至 32.7 億美元，預測期內複合年增長率 (CAGR) 為 2.9%。北美在 2024 年佔了 44.06% 的主導市場佔有率，這得益於其強大的醫療保健基礎設施、較高的公眾意識和大量的研發投入。

敗血症（血液中毒）是指感染性病原體進入血液，引起嚴重的全身性炎症，並可能發展為敗血症。隨著金黃色葡萄球菌、肺炎鏈球菌和大腸桿菌感染病例的持續增加，對高效抗生素的需求也不斷增加。院內感染、術後併發症、泌尿道感染、重症病患數量的增加，都是促使敗血症的重要因素。根據Science Direct 2025年6月的一項研究，在1085名住院患者中，16.7%患有細菌感染，這凸顯了促使膿毒症的疾病的普遍流行，並進一步強化了對抗生素治療的需求。

市場動態

成長因素

嚴重細菌感染（尤其是在兒童和老年族群）發病率的上升，仍然是市場成長的主要推動力。這些年齡層的免疫系統較弱，更容易發生血液感染。尿路感染是膿毒症的主要原因之一，其發生率在全球範圍內也在上升。根據泌尿科護理基金會（2022年11月）的數據，12%的男性和60%的女性一生中至少會經歷一次尿路感染，這增加了血液併發症的風險，並推動了對速效抗生素的需求。

限制因子

市場成長的最大障礙是抗菌素抗藥性（AMR）的快速成長。隨著細菌的演化，它們會對常用抗生素產生抗藥性，從而降低治療效果。 AMR會促使住院時間延長、死亡率升高和治療成本上升。美國國家生物技術資訊中心（2021年3月）報告稱，泌尿道感染中AMR的盛行率已達到53%，這凸顯了傳統抗生素的局限性日益擴大，以及它們在治療敗血症方面的療效下降。

機會

隨著抗藥性感染的快速增加，開發新型抗生素已成為全球優先事項。這為製藥公司、研究機構和政府支持的創新項目帶來了巨大的成長機會。 CARB-X計劃和抗菌藥物抗藥性行動基金正在加速抗生素的研究。 2024年1月，UTILITY Therapeutics公司宣布其用於治療泌尿道感染的抗生素PIVYA的新藥申請（NDA）已獲受理，該藥物由抗菌藥物抗藥性行動基金資助。這表明，各方正大力投資於能夠降低敗血症風險的下一代療法。

挑戰

敗血症的診斷仍然十分複雜。由於缺乏普遍認可的檢測方法，診斷主要依賴臨床症狀和多項檢查結果。根據MedPark醫院的報告顯示，診斷通常需要進行血液培養、腎功能檢查、X光檢查、CT掃描和MRI檢查。這種複雜性可能促使治療延誤、增加死亡風險，並阻礙及時使用抗生素。

市場趨勢

人工智慧驅動的診斷技術和藥物研發正成為變革性趨勢。人工智慧工具能夠提高細菌感染的快速檢測率，預測抗菌藥物抗藥性（AMR）模式，並加速新型候選抗生素的發現。根據2025年3月 "NPJ Journal" 的報告，人工智慧在傳染病診斷、AMR監測和抗生素藥物研發的應用預計將顯著增加，有助於提高敗血症治療的準確性。

細分市場洞察

依藥物類別

截至2024年，青黴素類藥物因其低毒性、價格實惠且對常見革蘭氏陽性菌有效而佔市場主導地位。

頭孢菌素類藥物憑藉其廣譜抗菌活性，預計將佔相當大的市場佔有率，並實現最快增長。頭孢地洛（Cefiderocol）於 2019 年獲得美國 FDA 批准，因其在治療泌尿道感染 (UTI) 和肺炎（敗血症的兩大主要病因）方面的療效而備受關注。

依給藥途徑

由於起效迅速，腸外抗生素佔了最大的市場佔有率，這在緊急情況下尤其重要。注射鹽酸萬古黴素是一種廣泛用於治療敗血症的腸外給藥藥物。

口服藥物因其方便性和價格優勢，在輕症患者中保持了穩定的市場佔有率。

按分銷管道

由於住院的重症感染患者數量不斷增加，預計到 2024 年，醫院藥房將佔市場主導地位。提供便利治療方案的零售藥局也佔了相當大的市場。

區域展望

由於感染意識高漲和研發投入強勁，北美市場規模預計在2024年達到11.5億美元。美國在該地區處於領先地位，這主要得益於其較高的膿毒症發病率以及人工智慧在診斷領域的先進應用。

根據歐洲疾病預防控制中心（ECDC）2024年的數據，歐洲佔醫院感染病例的很大一部分，每年病例達430萬例。

亞太地區是成長最快的地區，主要受泌尿道感染（UTI）盛行率上升和血流感染病例增加的推動。 2014年至2019年間，中國的血流感染病例增加了73%。

拉丁美洲和中東/非洲地區由於傳染病負擔加重和醫療保健服務可近性的提高，正經歷穩定成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 敗血症感染的流行病學
  • 主要國家和地區的報銷情況
  • 主要公司的研發管線分析
  • 主要公司的新產品發布
  • 主要產業趨勢，包括併購和合作

第五章：全球敗血症抗生素市場分析、洞察與預測（2019-2032）

  • 按藥物類別劃分的市場分析、洞察與預測
    • 青黴素類
    • 頭孢菌素類
    • 氟喹諾酮類
    • 醣肽類
    • 其他
  • 按給藥途徑劃分的市場分析、洞察與預測
    • 口服
    • 注射給藥
  • 按銷售管道劃分的市場分析、洞察與預測
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 按地區劃分的市場分析、洞察與預測
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美敗血症抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲敗血症抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區敗血症抗生素市場分析、洞察與預測2019-2032

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲敗血症抗生素市場分析、洞察與預測，2019-2032

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲敗血症抗生素市場分析、洞察與預測，2019-2032

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 中東其他地區以及非洲

第十一章 競爭分析

  • 全球市佔率分析（2024 年）
  • 公司簡介
  • 拜耳股份公司
  • STERIS HEALTHCARE PVT LTD
  • AdvaCare Pharma
  • Intelicure Lifesciences
  • Cipla
  • Mylan Institutional LLC
Product Code: FBI113752

Growth Factors of septicemia antibiotics Market

The global septicemia antibiotics market continues to expand as bacterial infections and bloodstream-related complications increase worldwide. According to the report, the market was valued at USD 2.61 billion in 2024, is projected to reach USD 2.67 billion in 2025, and is forecast to grow to USD 3.27 billion by 2032, reflecting a CAGR of 2.9% during the forecast period. In 2024, North America held the dominant share of 44.06%, supported by strong healthcare infrastructure, high awareness, and significant R&D spending.

Septicemia, or blood poisoning, occurs when infectious pathogens enter the bloodstream and trigger severe systemic inflammation that may progress to sepsis. As infections caused by Staphylococcus aureus, Streptococcus pneumoniae, and E. coli continue to rise, demand for effective antibiotics intensifies. Hospital-acquired infections, post-surgical complications, urinary tract infections, and a growing population of critically ill patients contribute significantly to septicemia cases. A June 2025 Science Direct study reported that 16.7% of 1,085 hospitalized patients had bacterial infections, highlighting the wide prevalence of conditions that can lead to septicemia and strengthening the need for antibiotic treatment.

Market Dynamics

Drivers

A rising incidence of severe bacterial infections, particularly among pediatric and geriatric populations, remains the key driver for market growth. These age groups have weaker immune systems and are more susceptible to bloodstream infections. Urinary tract infections-a major contributor to septicemia-are also increasing globally. According to the Urology Care Foundation (November 2022), 12% of men and 60% of women will experience at least one UTI in their lifetime, elevating the risk of bloodstream complications and the demand for fast-acting antibiotics.

Restraints

The biggest barrier to market growth is the sharp rise in antimicrobial resistance (AMR). As bacteria evolve, they develop resistance to commonly used antibiotics, reducing treatment effectiveness. AMR drives longer hospital stays, higher mortality rates, and elevated treatment costs. The National Center for Biotechnology Information (March 2021) reported 53% AMR prevalence in UTIs, highlighting the growing limitations of traditional antibiotics and their diminishing impact on septicemia treatment.

Opportunities

With antibiotic-resistant infections rising sharply, there is an urgent global need for novel antibacterial drugs. This offers significant growth opportunities for pharmaceutical companies, research institutions, and government-supported innovation programs. The CARB-X initiative and AMR Action Fund are accelerating antibiotic research. In January 2024, UTILITY Therapeutics announced acceptance of its NDA for PIVYA, an antibiotic for UTI management, backed by AMR Action Fund financing-demonstrating strong investment in next-generation therapies that can also reduce septicemia risk.

Challenges

Diagnosing septicemia remains complex, as there is no universally accepted test and diagnosis relies heavily on clinical presentation and multiple laboratory assessments. MedPark Hospital reports that diagnosis often requires blood cultures, kidney function tests, X-rays, CT scans, MRIs, and more. These complexities can delay treatment, increasing the risk of mortality and limiting timely adoption of antibiotics.

Market Trends

AI-driven diagnostics and drug discovery are emerging as transformative trends. AI tools improve rapid detection of bacterial infections, predict AMR patterns, and accelerate identification of new antibiotic candidates. According to the NPJ Journal (March 2025), AI adoption is expected to rise significantly for infection diagnostics, AMR surveillance, and antibiotic discovery-improving precision in septicemia treatment.

Segmentation Insights

By Drug Class

Penicillin dominated the market in 2024 due to its low toxicity, affordability, and effectiveness against common gram-positive bacteria.

Cephalosporins held a significant share and are expected to grow fastest due to broad-spectrum activity. Cefiderocol, approved by the U.S. FDA in 2019, is noted for its effectiveness in treating UTIs and pneumonia-major causes of septicemia.

By Route of Administration

Parenteral antibiotics accounted for the largest market share, driven by rapid onset of action required in emergency settings. Injectable Vancomycin Hydrochloride is a commonly used parenteral agent for septicemia.

The oral segment retained steady adoption due to convenience and affordability in milder cases.

By Distribution Channel

Hospital pharmacies dominated in 2024, supported by rising hospital admissions for severe infections. Retail pharmacies also held a significant share, offering accessible treatment options.

Regional Outlook

In 2024, North America generated USD 1.15 billion, driven by high infection awareness and strong R&D investments. The U.S. leads the region due to high septicemia incidence and advanced adoption of AI for diagnostics.

Europe holds a significant share, with 4.3 million annual hospital-acquired infection cases, according to ECDC 2024 data.

Asia Pacific is the fastest-growing region, driven by rising UTI prevalence and increasing bloodstream infections-China saw a 73% rise in BSI cases from 2014 to 2019.

Latin America and Middle East & Africa show steady growth due to rising infectious disease burden and improving healthcare access.

Conclusion

Growing from USD 2.61 billion in 2024 to USD 3.27 billion by 2032, the septicemia antibiotics market will remain vital as global infection rates rise, research investment accelerates, and new antibiotic products enter the market.

Segmentation By Drug Class

  • Penicillin
  • Cephalosporin
  • Fluoroquinolones
  • Glycopeptides
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Septicemia Infection
  • 4.2. Reimbursement Scenario, By Key Countries/Regions
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Penicillin
    • 5.1.2. Cephalosporin
    • 5.1.3. Fluoroquinolones
    • 5.1.4. Glycopeptides
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail Pharmacy
    • 5.3.3. Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Penicillin
    • 6.1.2. Cephalosporin
    • 6.1.3. Fluoroquinolones
    • 6.1.4. Glycopeptides
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail Pharmacy
    • 6.3.3. Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Penicillin
    • 7.1.2. Cephalosporin
    • 7.1.3. Fluoroquinolones
    • 7.1.4. Glycopeptides
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Penicillin
    • 8.1.2. Cephalosporin
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Glycopeptides
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Penicillin
    • 9.1.2. Cephalosporin
    • 9.1.3. Fluoroquinolones
    • 9.1.4. Glycopeptides
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Septicemia Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Penicillin
    • 10.1.2. Cephalosporin
    • 10.1.3. Fluoroquinolones
    • 10.1.4. Glycopeptides
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Bayer AG
    • 11.2.2. STERIS HEALTHCARE PVT LTD
    • 11.2.3. AdvaCare Pharma
    • 11.2.4. Intelicure Lifesciences
    • 11.2.5. Cipla
    • 11.2.6. Mylan Institutional LLC

List of Tables

  • Table 1: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 2: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 3: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 6: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 7: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 10: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 11: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 14: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 15: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 18: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 19: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 22: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 23: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Septicemia Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Septicemia Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024 & 2032
  • Figure 3: Global Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024 & 2032
  • Figure 4: Global Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Septicemia Antibiotics Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 7: North America Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 8: North America Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 9: North America Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 10: North America Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Septicemia Antibiotics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Septicemia Antibiotics Market Value Share (%), By Country, 2024
  • Figure 14: Europe Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 15: Europe Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 16: Europe Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 17: Europe Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 18: Europe Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 23: Asia Pacific Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 24: Asia Pacific Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 25: Asia Pacific Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 26: Asia Pacific Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 31: Latin America Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 32: Latin America Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 33: Latin America Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 34: Latin America Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 39: Middle East & Africa Septicemia Antibiotics Market Value Share (%), By Drug Class, 2024
  • Figure 40: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 41: Middle East & Africa Septicemia Antibiotics Market Value Share (%), By Route of Administration, 2024
  • Figure 42: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Septicemia Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Septicemia Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Septicemia Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Septicemia Antibiotics Market Share (%), By Company, 2024